KeyBanc analyst Brett Fishbin lowered the firm’s price target on ICU Medical (ICUI) to $191 from $209 and keeps an Overweight rating on the shares. The firm believes underlying MedTech trends remain mostly positive heading into Q1 earnings season, but is lowering several price targets to reflect macro concerns around the potential impact of tariffs as well as an increased risk of recession.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ICUI:
- ICU Medical announces FDA 510(k) clearance for Plum Solo, Plum Duo pumps
- ICU Medical added to Analyst Current Favorites list at Raymond James
- ICU Medical upgraded to Strong Buy from Outperform at Raymond James
- ICU Medical’s Earnings Call: Growth Amid Challenges
- ICU Medical Reports Revenue Growth Amid Net Loss
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue